Kazia Therapeutics Limited is a biotechnology firm primarily dedicated to creating pharmaceutical treatments for cancer. Its leading therapeutic asset is Paxalisib, a distinctive small molecule that can penetrate the brain and works by inhibiting the PI3K/Akt/mTor pathway, showing promise as a potential remedy for glioblastoma. The company is also progressing with EVT801, an experimental medication being investigated for its efficacy against various cancer types. Incorporated in 1994, the entity operated under the name Novogen Limited until its rebranding to Kazia Therapeutics Limited in November 2017. The company's main operations are based in Sydney, Australia.